孕烷X受体
雄激素受体
法尼甾体X受体
核受体
G蛋白偶联胆汁酸受体
胆汁酸
药物代谢
CYP8B1
骨化三醇受体
药品
肝受体同系物-1
生物
运输机
胆固醇7α羟化酶
受体
肝X受体
鹅去氧胆酸
肝细胞核因子4
药理学
生物化学
基因
转录因子
作者
Jeff L. Staudinger,Sarah K. Woody,Mengxi Sun,Wenqi Cui
标识
DOI:10.3109/03602532.2012.748793
摘要
Adverse drug events (ADEs) are a common cause of patient morbidity and mortality and are classically thought to result, in part, from variation in expression and activity of hepatic enzymes of drug metabolism. It is now known that alterations in the expression of genes that encode drug- and bile-acid-transporter proteins in both the gut and liver play a previously unrecognized role in determining patient drug response and eventual clinical outcome. Four nuclear receptor (NR) superfamily members, including pregnane X receptor (PXR, NR1I2), constitutive androstane receptor (NR1I3), farnesoid X receptor (NR1H4), and vitamin D receptor (NR1I1), play pivotal roles in drug- and bile-acid-activated programs of gene expression to coordinately regulate drug- and bile-acid transport activity in the intestine and liver. This review focuses on the NR-mediated gene activation of drug and bile-acid transporters in these tissues as well as the possible underlying molecular mechanisms.
科研通智能强力驱动
Strongly Powered by AbleSci AI